We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access Program of Ponatinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01592136
Expanded Access Status : Approved for marketing
First Posted : May 7, 2012
Last Update Posted : February 6, 2018
Sponsor:
Information provided by (Responsible Party):
Takeda ( Ariad Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This protocol will allow expanded access of ponatinib to patients ≥18 years with chronic myeloid leukemia (CML) any phase or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) who have failed all available treatment options.

Condition or disease Intervention/treatment
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Drug: ponatinib

Detailed Description:
This protocol will allow expanded access of ponatinib to patients ≥18 years with CML or Ph+ALL who have failed all available treatment options. Patients with chronic (CP) or accelerated phase (AP) CML must be previously treated with and resistant or intolerant to imatinib, dasatinib and nilotinib or develop the T315I mutation after any tyrosine kinase inhibitor (TKI) therapy. Patients with blast phase (BP) CML and Ph+ ALL must be previously treated with and resistant or intolerant to imatinib and dasatinib or develop the T315I mutation after any TKI therapy. No formal analysis will be performed on any data obtained. Safety information will be collected and adverse events will be tabulated for reporting purposes only.
Study Design
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Expanded Access
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Expanded Access Program of Ponatinib (AP24534) for Patients With Refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia

Resource links provided by the National Library of Medicine


Interventions
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Drug: ponatinib
    Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
    Other Name: AP24534
Eligibility Criteria
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Main Inclusion Criteria:

  1. CP-CML and AP-CML patients previously treated with and resistant or intolerant to imatinib, dasatinib and nilotinib or those who developed the T315I mutation after any TKI therapy. BP-CML and Ph+ ALL patients previously treated with and resistant or intolerant to imatinib and dasatinib or those who developed the T315I mutation after any TKI therapy.
  2. Patients must be ≥ 18 years old.
  3. Provide written informed consent.
  4. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
  5. Men and women of childbearing potential must agree to effective contraception from the time of signing informed consent through the Follow-up Visit, approximately 30 days after last dose of ponatinib.

Main Exclusion Criteria:

Patients are not eligible for participation in the study if they meet any of the following exclusion criteria:

  1. Are eligible for an ongoing and accessible clinical trial of ponatinib
  2. Have not adequately recovered from AEs due to agents previously administered
  3. Require concurrent treatment with immunosuppressive agents, other than corticosteroids prescribed for a short course of therapy.
  4. Have previously been treated with ponatinib.

  5. Have significant or active cardiovascular disease, specifically including, but not restricted to:

    • Myocardial infarction within 3 months prior to first dose of ponatinib,
    • History of clinically significant atrial arrhythmia or any ventricular arrhythmia,
    • Unstable angina within 3 months prior to first dose of ponatinib,
    • Congestive heart failure within 3 months prior to first dose of ponatinib.
  6. Have abnormal QTcF (> 450 ms for males or > 470 ms for females)
  7. Have a significant bleeding disorder unrelated to CML or Ph+ ALL.
  8. Have a history of pancreatitis or alcohol abuse
  9. Have elevated amylase or lipase (> 1.5 x ULN for institution) at entry.

  10. Have inadequate hepatic function or any of the following:

    • Total bilirubin > 1.5 x ULN for institution at entry
    • Alanine aminotransferase and aspartate aminotransferase > 2.5 x ULN for institution at entry
    • Prothrombin time >1.5 x ULN for institution at entry
  11. Have inadequate renal function or serum creatinine > 2.5 x ULN for institution at entry
  12. Have uncontrolled hypertriglyceridemia or triglycerides > 450 mg/dL at entry.
  13. Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of orally administered ponatinib.
  14. Women who are pregnant or lactating.
  15. Underwent major surgery within 14 days prior to the first dose of ponatinib.
  16. Have ongoing or active infection (including known history of human immunodeficiency virus [HIV], hepatitis B virus [HBV], or hepatitis C virus [HCV]).
  17. Suffer from any condition or illness that, in the opinion of the Investigator would compromise patient safety or interfere with the evaluation of the safety of the study drug.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01592136


Locations
Show Show 33 study locations
Sponsors and Collaborators
Ariad Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Interventions Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Ariad Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01592136    
Other Study ID Numbers: AP24534-12-901
First Posted: May 7, 2012    Key Record Dates
Last Update Posted: February 6, 2018
Last Verified: February 2018
Keywords provided by Takeda ( Ariad Pharmaceuticals ):
Ponatinib
Tyrosine kinase inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Philadelphia Chromosome
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
 Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Translocation, Genetic
Chromosome Aberrations
Pathologic Processes
Ponatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action